peplomycin and Lymphoma

Pulmonary toxicity was less frequent in pepleomycin treatment of squamous cell carcinoma than in bleomycin treatment. The tumor-regressing effect appeared at about day 10 of pepleomycin treatment, and at about day 21 of bleomycin treatment. The cumulative dose of pepleomycin to complete remission was smaller than that of bleomycin. Pepleomycin is effective against bleomycin-sensitive malignancies: squamous cell carcinoma and Hodgkin's disease. It is more effective than bleomycin against lymph node metastases. Pepleomycin may have a broader antitumor spectrum: prostatic carcinoma responded.

Topics: Antibiotics, Antineoplastic; Bleomycin; Drug Evaluation; Drug Resistance; Female; Head and Neck Neoplasms; Humans; Lymphoma; Male; Middle Aged; Neoplasm Metastasis; Peplomycin; Prostatic Neoplasms; Skin Neoplasms

From November 1993 to December 1994, a prospective multi-centre phase II clinical trial was done in 137 patients with advanced cancer on China-made pepleomycin (PEP). PEP was effective in patients with cancer of the head and neck, malignant lymphmo and lung cancer, with response rate of 66.7%, 50% and 30%, respectively. The major adverse reactions were fever and mild gastrointestinal reaction. In the controlled study of combination chemotherapy with China-made and Japan-made PEP, the response rates and side effects were similar. The results indicate that China made PEP can be used in lieu of that made in Japan.

Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphoma; Male; Middle Aged; Peplomycin; Prospective Studies

Twelve patients with relapsed or refractory malignant lymphoma were treated with IMV-triple P regimen consisting of ifosfamide (IFM), mitoxantrone (MIT), vindesine (VDS), pepleomycin (PEP), procarbazine (PCZ) and prednisolone (PDN). Three of 12 patients achieved complete remission (CR), and 5 patients achieved partial remission (PR). Hence, the overall response rate was 66.7% (8/12). Of 9 relapsed patients who had attained CR after the former chemotherapy, 3 had CR and 4 had PR. The overall response rate was 77.8% (7/9). Side effects were relatively mild, including leukopenia (less than 1,000/microliters) (33.3%) and thrombocytopenia (less than 5 X 10(4)/microliters) (8.3%). There was no severe cardiac toxicity such as heart insufficiency and severe arrythmia. These results suggest that IMV-triple P regimen is effective in the treatment of relapsed or refractory malignant lymphoma.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Female; Heart; Humans; Ifosfamide; Leukopenia; Lymphoma; Male; Middle Aged; Mitoxantrone; Peplomycin; Prednisolone; Procarbazine; Remission Induction; Survival Rate; Thrombocytopenia; Vindesine

Topics: Animals; Bleomycin; Drug Resistance, Microbial; Lymphoma; Mice; Peplomycin; Tumor Cells, Cultured

Spirometric parameters and transfer lung factor for carbon monoxide (TLCO) were determined in 14 cancer patients treated with pepleomycin at the dose of 10 mg twice weekly up to the cumulative dose of 200 mg. Mean values recorded after completion of therapy did not significantly differ from those recorded before treatment. Three patients pretreated with bleomycin had a fall in TLCO of more than 20% of pretreatment values. Three patients (2 of them pretreated with bleomycin) showed radiologic signs of pulmonary toxicity without instrumental signs of lung toxicity. In patients with no risk factors, no significant modifications in the tested parameters were observed after completion of therapy. These preliminary results suggest that, in the absence of risk factors, pepleomycin, may have no significant pulmonary toxicity at least up to the cumulative dose of 200 mg.

Topics: Adult; Aged; Bleomycin; Female; Head and Neck Neoplasms; Humans; Lung; Lymphoma; Male; Middle Aged; Peplomycin; Pulmonary Gas Exchange; Risk Factors; Vital Capacity

Malignant lymphoma of the left testis was seen in a 53-year-old man. Pathologically, the tumor cell showed malignant lymphoma of the diffuse, small cell type, especially, of lympho-plasmacytoid in LSG classification. Clinically, no other lesions were found. At 26 months following orchiectomy with chemotherapy (CHOP regimen: cyclophosphamide, hydroxydaunomycine, vincristine and prednisone) as well as post-operative irradiation (60Co, 30 Gy.), the patient has been doing well without any clinical evidence of recurrence generalization of the tumor.

Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cobalt Radioisotopes; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Humans; Lymphoma; Male; Orchiectomy; Peplomycin; Plasma Cells; Testicular Neoplasms; Vinblastine

Twenty-three patients with squamous cell carcinoma were treated with a combination chemotherapy consisting of cisplatin, vincristine, and peplomycin. Overall response rate was over 70% including complete disappearance of tumors in one patient. Peplomycin was given by continuous i.v. or s.c. infusion using a micro-infusion pump. All the patients experienced some degree of nausea, vomiting, and hair loss. Phlebitis and induration of injection sites with subsequent local pigmentation were frequently encountered. Nausea and vomiting were caused mainly by cisplatin, but more than 60% of the patients experienced transient increase of anorexia or nausea in the period of peplomycin administration. Eruption with skin excoriation or pigmentation along scratch dermatitis were seen in 5 patients. These side effects were well tolerated, and high fever which is commonly observed in one-shot therapy did not develop in any patient. Pulmonary fibrosis was also not seen. Peplomycin should be given by low-dose continuous infusion because of its low toxicity and comparable antineoplastic activity to one-shot therapy.

Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Eruptions; Female; Humans; Infusions, Parenteral; Lymphoma; Male; Middle Aged; Peplomycin; Phlebitis; Vincristine

Seventeen patients with malignant lymphoma were entered into a phase II study of peplomycin (PEP) to determine the efficacy of the drug. There were 8 males and 9 females with a median age of 64 yrs (range 3-74 yrs) and a median PS 3 (range 2-4). Three of these were children. At first PEP was given intermittently and intramuscularly (8 cases) at a dose of 10 mg every one (3 cases) or two (5 cases) weeks, and then intravenously by 22-hr continuous infusion (9 cases) at a dose of 5 mg per day for 5 days. Mean cumulative dose was 78 mg. Objective responses were obtained in 6 patient (35%). CR lasting 4 weeks was obtained in one patient with diffuse mixed-type lymphoma. Five patients, one with diffuse medium-sized cell type and 3 with diffuse large cell type, had PR, lasting 6, 7, 7, 9, and 50+ weeks, respectively. Pulmonary fibrosis was found in two patients on autopsy and interstitial pneumonia in two patients clinically. Temporary high fever occurred in 7 patients, stomatitis in 3 patients and anorexia in 3 patients.

Topics: Adolescent; Adult; Aged; Anorexia; Bleomycin; Child, Preschool; Drug Evaluation; Female; Fever; Humans; Infusions, Parenteral; Injections, Intramuscular; Lymphoma; Male; Middle Aged; Peplomycin; Stomatitis

Five mg of peplomycin was administered continuously for 24 hours by intravenous or subcutaneous infusion. Subcutaneous administration of peplomycin was performed done with the use of an SP-5 microinfusion pump made by the in Nipro Company. The plasma concentration after intravenous infusion was 0.0106 +/- 0.039 microgram/ml, while that after subcutaneous infusion was 0.131 +/- 0.037 microgram/ml. There was no statistical significance between the differences observed for intravenous and subcutaneous infusion.

Topics: Antibiotics, Antineoplastic; Bleomycin; Esophageal Neoplasms; Female; Humans; Infusions, Parenteral; Lymphoma; Male; Neoplasms; Peplomycin; Prostatic Neoplasms

It is often very frustrating for clinicians when in cases where Hodgkin's disease or non-Hodgkin's lymphoma is relapsing rapidly, sufficient doses of cytotoxic agents and/or radiation therapy cannot be given because of cytopenia due either to previous treatment or to bone marrow infiltration by the lymphoma. We have been treating such patients with a combination chemotherapy consisting of vincristine 0.25 mg/day i.v. push daily for 4 days, pepleomycin 5 mg/day s.c. by continuous infusion daily for 4 days, and prednisolone 1 g/day p.o. or methylprednisolone 1 g/day d.i.v. every other day for 4 days POP combination) administered every 2 to 3 weeks until an improvement in cytopenia occurs. Twelve patients with advanced non-Hodgkin's lymphoma, including 8 T-cell lymphoma patients, entered this pilot study when they were cytopenic or had been treated with cytotoxic agents or radiation therapy immediately prior to POP therapy. All patients responded and experienced more than 50% tumor reduction associated with improved general condition. Untoward effects included transient glycosuria, mild decline of serum immunoglobulin levels, herpes zoster and temporary aggravation of cutaneous or oral fungal infection in each of one to two patients. Since this treatment is switched to other forms of treatment when bone marrow function has recovered, duration of the response cannot be determined. The survival time was rather short because of poor general condition and aggravation of concurrent active pulmonary infection before the start of treatment. This treatment is sufficient effective, however, to be tried on patients with active lymphoma, not necessarily associated with poor bone marrow function, unless active infection supervention.

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Female; Glucocorticoids; Humans; Lymphoma; Male; Middle Aged; Peplomycin; Vincristine

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Female; Gastrectomy; Humans; Lymphoma; Male; Middle Aged; Peplomycin; Prednisone; Stomach Neoplasms; Vincristine

Peplomycin containing combination chemotherapy with cyclophosphamide, hydroxy-daunomycin, oncovin and prednisone (CHOP-P) was performed in one patient with ATL and 8 patients with advanced diffuse lymphoma. CHOP-PM combination chemotherapy plus MTX was applied to 6 patients resistant to CHOP-P regimen. The overall complete remission rate was 53%, and 67% in non-T cell type and 50% in T cell type. However, only one patient out of 4 ATL patients showed complete response. Toxicities such as transient fever, myelotoxicities, G-I tract symptoms, hair loss and interstitial pneumonitis, were observed. Only in one out of 4 patients suspected drug-induced pneumonitis by peplomycin was observed. This regimen including peplomycin is considered to be one of the useful combination chemotherapies for diffuse lymphoma, especially non-T cell type and some of T cell type, except ATL.

Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Leukemia; Lung; Lymphoma; Male; Middle Aged; Peplomycin; Prednisone; Radiography; T-Lymphocytes; Vincristine

NK-631 (Peplomycin) has an anti-tumor spectrum, equivalent to or higher than its analogue bleomycin and low toxicities to the lungs. Fourteen patients with advanced non-Hodgkin's lymphoma received NK-631 10 to 30 mg once or twice a week. As the results, there were 57.1% response rate of all patients. The response rate according to the immunologic classification were 100%(6/6 cases) for patients with non-T cell lymphoma and 25%(2/8 cases) for patients with T-cell lymphoma. On the other hand, we observed some toxicities such as transient fever in 64.3%, G-I tract symptoms in 21.4%, skin toxicities in 21.4% and pulmonary fibrosis in one case. This agent is considered to be one of the useful agents to non-Hodgkin's lymphoma especially non-T cell lymphoma.

Topics: Adult; Aged; Antibiotics, Antineoplastic; Bleomycin; Drug Evaluation; Female; Humans; Lymphoma; Male; Middle Aged; Peplomycin; T-Lymphocytes

From experimental observations, Peplomycin was expected to be more active against a variety of tumors and to be less toxic for the lung than the parent compound. An intermittent dose(10mg. twice a week) of peplomycin was tested in patients with malignant lymphoma or squamous cell carcinoma who had failed conventional treatment. There were two cases of CR and five cases of PR in twelve cases with malignant lymphoma, and two cases of PR in fourteen cases with squamous cell carcinoma. Out of 26 cases treated with peplomycin, fever was seen in ten cases(38.5%) and pulmonary complication was seen in five cases (19.2%). These data obtained from peplomycin treatment were compared with the results obtained from our previous experiences with bleomycin. Response rate, spectrum and frequency of side reactions of peplomycin treatment were substantially identical with those of bleomycin treatment. However, remission duration and life span were much longer in peplomycin treatment. In this respect, peplomycin seems to be superior than bleomycin to a certain extent.

Topics: Adult; Aged; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Squamous Cell; Female; Humans; Lymphoma; Male; Middle Aged; Peplomycin

1. The therapeutic effects of pepleomycin seem superior to those achieved with bleomycin against squamous cell carcinoma and malignant lymphoma. 2. In basal cell epithelioma, carcinoma in situ (e.g., actinic keratosis, Bowen's disease), adenocarcinoma (e.g., mammary and genital Paget's disease), and adult soft tissue sarcoma, pepleomycin as well as bleomycin was clinically ineffective. 3. Of the two cases of stage IV malignant melanoma, pepleomycin combined with MeCCNU and VCR exerted a moderate effect against multiple disseminated skin metastases in one, and a slight effect against a VI rib metastasis in the other. 4. The sorts of side effects of pepleomycin were almost the same as those of bleomycin. Lung toxicities were less frequent under pepleomycin treatment than those under bleomycin treatment.

Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Japan; Lymphoma; Male; Melanoma; Middle Aged; Peplomycin; Skin Neoplasms